Federal inspectors responding to a complaint in November found that staff had discovered the medication swap in July but never filed a required incident report with Ohio health officials. The facility's own contracted pharmacist confirmed that oxycodone tablets had been removed from blister packs and replaced with Loratadine, a common over-the-counter allergy medication.
The discovery came during a routine medication inspection when staff noticed something unusual about Resident 50's pain medication packaging. Thirty bubble packs containing the resident's prescribed oxycodone showed clear signs of tampering on the reverse side of the cards.
Fifteen of those bubbles contained slits in the backing material.
The facility's director of nursing remained present while inspectors examined the compromised blister cards. The contracted pharmacist who conducted the initial investigation in July had determined that the 15 oxycodone tablets originally contained in those slit bubbles had been replaced with Loratadine 10 mg tablets.
When the facility's pharmacist arrived on-site on July 16 to inspect the medication cards, he confirmed the substitution. He provided inspectors with a copy of an email from the contracted pharmacist documenting what had been found during that visit. The email became part of the facility's internal investigation file.
The director of nursing told inspectors he could not confirm that misappropriation of the resident's medication had occurred because the facility's investigation failed to prove who had taken the oxycodone. He maintained this position despite acknowledging a crucial fact: facilities don't need to identify the specific person responsible to establish that medication theft has occurred.
"He acknowledged they did not have to prove who took the medication to show evidence of misappropriation of a resident's medication had occurred, only that there were doses unaccounted for that had not been used by the resident," inspectors wrote.
The director admitted he had not submitted a self-reporting incident to the state survey agency regarding the suspected medication diversion. He explained that he didn't feel the facility's investigation had determined that misappropriation actually occurred.
Yet he also acknowledged that some of Resident 50's oxycodone had indeed been replaced with allergy medication. Those missing oxycodone tablets were never used by the resident as prescribed.
The facility's own abuse prohibition policy defines misappropriation of resident property as "depriving, defrauding, or otherwise obtaining the real or personal property of a resident by any means prohibited by the Revised Code." The policy also describes it as "the patterned or deliberate misplacement, exploitation, or wrongful, temporary or permanent use of a resident's belongings or money without the resident's consent."
Under facility policy, all alleged violations involving abuse, neglect, and misappropriation must be immediately reported to the administrator or designee. The policy requires reporting allegations involving abuse or serious bodily injury to the Ohio Department of Health as soon as possible, but no more than two hours after discovery.
For allegations not involving abuse or serious bodily injuries, facilities have up to 24 hours to report. The results of thorough investigations must be reported to state health officials within five working days of the incident.
None of this happened.
The medication substitution represented a clear violation of the resident's right to receive prescribed pain management as ordered by their physician. Oxycodone, a controlled substance used to treat moderate to severe pain, has entirely different therapeutic properties than Loratadine, which treats allergies and has no pain-relieving effects.
The physical evidence was unambiguous. Fifteen blister pack bubbles showed deliberate slits in their backing material. The original oxycodone tablets were gone. Allergy pills sat in their place.
Someone with access to the resident's medication had systematically opened the sealed packaging, removed controlled substances, and substituted them with over-the-counter pills. The process would have required both opportunity and intent to conceal the theft by making the packaging appear intact from the front.
The facility's contracted pharmacist, who serves as an independent professional observer, confirmed the substitution after conducting his own examination. His email documentation provided an objective record of the findings.
Despite this evidence chain, the director of nursing drew a distinction between proving individual responsibility and acknowledging that medication theft had occurred. He insisted the facility couldn't report suspected misappropriation without identifying the specific person responsible.
This reasoning contradicted the facility's own policy requirements and state reporting standards. Regulatory frameworks recognize that medication diversion can be documented and reported based on evidence of tampering and substitution, regardless of whether investigations identify specific perpetrators.
The resident whose medication was compromised may have experienced inadequate pain control during the period when oxycodone tablets were replaced with ineffective substitutes. The facility's failure to report the incident also prevented state authorities from conducting their own investigation and implementing protective measures.
Federal inspectors classified the violation as causing minimal harm or potential for actual harm, affecting few residents. However, the incident raised broader questions about medication security protocols and staff oversight at the facility.
The inspection occurred in response to a complaint filed with federal authorities. The medication substitution investigation fell under Complaint Number 2672468, indicating that external concerns had prompted regulatory scrutiny of the facility's practices.
Resident 50's compromised pain medication represents both a theft of prescribed controlled substances and a failure of the systems designed to protect vulnerable nursing home residents from exploitation.
The oxycodone tablets, wherever they ended up, never reached the resident who needed them for pain management.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Belpre Landing Nursing and Rehabilitation from 2025-11-24 including all violations, facility responses, and corrective action plans.
Additional Resources
- View all inspection reports for Belpre Landing Nursing and Rehabilitation
- Browse all OH nursing home inspections